NEW YORK (GenomeWeb News) – Contract research organization Reaction Biology (RBC) said today that it has signed an agreement with Cisbio Bioassays for distribution of its epigenetic proteins.
The agreement gives Cisbio global rights to co-market and sell RBC's epigenetic proteins. Cisbio can include these proteins in its portfolio of assays, including recently added assays for assessing epigenetic targets like methyltransferases.
According to RBC, the company has one of the largest collections of recombinant human epigenetic proteins, a class of analytes that is currently the subject of considerable pharmaceutical interest as potential cancer drug targets.
"RBC's portfolio of epigenetic proteins is projected to grow to over 200 this year," Haiching Ma, RBC chief scientific officer, said in a statement. "With more and more international interest, we felt a relationship with an outstanding distributor like Cisbio would bring these proteins to the widest possible client base."
"We have been seeing increasing demand for high-quality epigenetic proteins that can be included in the assays that we currently develop," noted Patrick Seguin, Cisbio's vice president of sales and marketing.
Financial and other terms of the agreement were not disclosed.